Vivek Subbiah: Holiday party with the next generation of future doctors and medicine residents
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“One of the best-kept secrets in Nashville is Parnassus Books, an incredible independent bookstore.
I am so thankful for the invite to the holiday party at the bookstore with the next generation of future doctors and medicine residents from the amazing Dr. Karl VanDevender.
As Alan Alda says, Dr. Karl VanDevender is one of the most empathetic physicians of our times.
Always exhilarating discussions with him!”
More posts featuring Vivek Subbiah.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023